Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.48 (
transcriptase
)
9,479
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mitogen-activated protein kinase (MAPK) pathway plays a major role in pediatric low-grade gliomas (pLGGs). Immunohistochemistry with mutant-specific antibody, VE1, has appeared to be the most affordable and rapidly deployable method to identify tumors with aberrant MAPK signaling pathway, by highlighting tumor with BRAF
V600E
mutation. Nonetheless, positive staining cases but not associated with BRAF
V600E
mutation are also seen. We analyzed 62 pLGGs for the two commonest genetic aberrations in MAPK pathway:
KIAA1549
-BRAF fusion, using reverse-
transcriptase
polymerase chain reaction, and BRAF
V600E
mutation, using VE1 antibody and Sanger sequencing. We recorded a specificity and accuracy rate of 68.75% and 75%, respectively, for VE1, when strong cytoplasmic staining is observed. Interestingly, we observed that cells with ganglionic features frequently bind VE1 but not associated with BRAF
V600E
mutation. Such observation was also confirmed in four cases of differentiating neuroblastoma. This false positive staining may serve as an important confounder in the interpretation of VE1 immunoreactivity with major therapeutic implication. It is important to confirm the presence of BRAF
V600E
mutation by DNA-based method, especially in tumor entities not known to, or rarely harbor such mutations.
...
PMID:Cells with ganglionic differentiation frequently stain for VE1 antibody: a potential pitfall. 3182 Jan 33
